Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
113.16
-0.84 (-0.74%)
At close: Mar 28, 2025, 4:00 PM
112.00
-1.16 (-1.03%)
Pre-market: Mar 31, 2025, 8:51 AM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for Neurocrine Biosciences stock have an average target of 166.75, with a low estimate of 114 and a high estimate of 219. The average target predicts an increase of 47.36% from the current stock price of 113.16.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock from 21 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 6 | 5 | 6 | 6 |
| Buy | 11 | 11 | 11 | 11 | 11 | 11 |
| Hold | 5 | 5 | 5 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 24 | 22 | 21 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $183 → $184 | Buy | Maintains | $183 → $184 | +62.60% | Mar 26, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $185 → $150 | Buy | Initiates | $185 → $150 | +32.56% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $185 | Strong Buy | Reiterates | $185 | +63.49% | Feb 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $185 | Strong Buy | Reiterates | $185 | +63.49% | Feb 21, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $165 → $163 | Strong Buy | Maintains | $165 → $163 | +44.04% | Feb 10, 2025 |
Financial Forecast
Revenue This Year
2.73B
from 2.36B
Increased by 16.08%
Revenue Next Year
3.17B
from 2.73B
Increased by 15.87%
EPS This Year
4.46
from 3.29
Increased by 35.56%
EPS Next Year
6.55
from 4.46
Increased by 46.92%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.9B | 3.5B | 4.4B | ||
| Avg | 2.7B | 3.2B | 3.6B | ||
| Low | 2.6B | 2.8B | 3.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 22.9% | 29.8% | 38.3% | ||
| Avg | 16.1% | 15.9% | 14.6% | ||
| Low | 8.9% | 1.7% | -2.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.56 | 9.64 | 14.84 | ||
| Avg | 4.46 | 6.55 | 9.09 | ||
| Low | 2.52 | 3.45 | 3.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 99.5% | 116.1% | 126.4% | ||
| Avg | 35.6% | 46.9% | 38.7% | ||
| Low | -23.4% | -22.7% | -47.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.